Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Kangpu Biopharmaceuticals, Ltd. logo — company profile

Kangpu Biopharmaceuticals, Ltd.

Founded 2011 China China 14 employees Series B Total: $364.00M Biopharma, Health Care +1

General Information

Company Name Kangpu Biopharmaceuticals, Ltd.
Founded Year 2011
Location China China
Employees 14
Industries Biopharma, Health Care, Pharmaceutical
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Kangpu Biopharmaceuticals, Ltd.. To contact Kangpu Biopharmaceuticals, Ltd., visit kangpugroup.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Kangpu Biopharmaceuticals, Ltd.

Kangpu Biopharmaceuticals, Ltd. is a China-based biopharmaceutical startup founded in 2011. The company focuses on developing innovative small molecules for treating solid tumors, hematological malignancies, auto-immune diseases, and inflammatory disorders. It specializes in targeted protein ubiquitination and degradation, offering novel-generation solutions. Kangpu has a strong management team and a robust pipeline of potential first-in-class and best-in-class drug candidates. One of its notable developments is X-Synergy®, a proprietary drug combination technology for treating metastatic and non-metastatic castration-resistant prostate cancer.

Notably, Kangpu recently received a substantial CNY100.00M Series B investment on 30 August 2023. The investment was led by Northern Light Venture Capital, Yijing Capital, 浙江银杏谷投资有限公司, Ruihe Capital, Longpan Investment, Yicun Capital, and Xiaochi Capital.

Taxonomy: Biopharmaceuticals, Clinical-stage company, Drug discovery, Small molecules, Cancer treatment, Autoimmune diseases, Inflammatory disorders, Targeted protein ubiquitination, Ubiquitin-protein degradation, X-Synergy®, Metastatic castration-resistant prostate cancer, Immuno-modulating drugs, Drug development, Precision medicine

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B CNY100.00M 7
Northern Light Venture Capital Yijing Capital 浙江银杏谷投资有限公司
Northern Light Venture Capital, Yijing Capital +5
30 Aug 2023
Series B CNY250.00M 3
Lapam Capital Shining Capital
Lapam Capital, Shining Capital +1
10 May 2021
Series A $14.00M -
09 Aug 2019

Kangpu Biopharmaceuticals, Ltd. Alternatives & Competitors

View All Alternatives
Kangpu Biopharmaceuticals, Ltd. vs
Inspirna, Inc.
Inspirna, Inc. United States

Converting cancer to a manageable, chronic condition

Series D
12 employees
Biotechnology, Health Care
Kangpu Biopharmaceuticals, Ltd. vs
Ventus Therapeutics
Ventus Therapeutics United States

Pioneering a unique approach to structure-based drug discovery. Located in Waltham, MA and Montreal,...

Grant
55 employees
Biotechnology, Health Care
Kangpu Biopharmaceuticals, Ltd. vs
Captor Therapeutics SA
Captor Therapeutics SA Poland

Captor Therapeutics aims to treat cancer, infections, and diseases by targeting the difficult-to-dru...

IPO
79 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Kangpu Biopharmaceuticals, Ltd.

Kangpu Biopharmaceuticals, Ltd. is a clinical-stage company focused on the discovery and development of innovative small molecules for the treatment of solid tumors, hematological malignancies, auto-immune diseases as well as inflammatory disorders through novel-generation solutions including target...
Kangpu Biopharmaceuticals, Ltd. was founded in 2011.
Kangpu Biopharmaceuticals, Ltd. is headquartered in China.
Kangpu Biopharmaceuticals, Ltd. operates in Biopharma, Health Care and Pharmaceutical. Its work centres on Biopharmaceuticals, Clinical-stage company, Drug discovery and Small molecules.
Kangpu Biopharmaceuticals, Ltd. has approximately 14 employees.
Kangpu Biopharmaceuticals, Ltd. has completed 3 funding rounds, raising a total of $364.00M. The latest funding stage is Series B.
Top alternatives and competitors to Kangpu Biopharmaceuticals, Ltd. include Inspirna, Inc., Ventus Therapeutics, Captor Therapeutics SA, BeyondSpring, Arvinas. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Kangpu Biopharmaceuticals, Ltd. and Inspirna, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Kangpu Biopharmaceuticals, Ltd., https://bouncewatch.com/company/kangpu-biopharmaceuticals-ltd, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes